三阴性乳腺癌TEC方案新辅助化疗临床疗效观察被引量：1

在线阅读下载PDF

导出

摘要目的评价紫杉醇或多西他赛联合表柔比星和环磷酰胺（TEC）新辅助治疗三阴性乳腺癌的临床疗效和毒性反应。方法 38例三阴性乳腺癌患者在术前接受新辅助治疗,方案为紫杉醇或多西他赛联合表柔比星和环磷酰胺3周方案,术前化疗2-6个周期,观察近期疗效和毒副反应。结果 38例患者接受2-6个周期TEC方案的新辅助化疗,总有效率86.8%;9例达CR（23.7%）,24例PR（63.2%）,另有3例SD（7.9%）,2例PD（5.3%）。经手术后病理证实,本组有7例（18.4%）达到p CR。Ⅲ、Ⅳ度中性粒细胞减少分别占39.5%和28.9%,5例（13.2%）患者出现中性粒细胞减少性发热。常见的非血液系统不良反应为脱发、恶心或呕吐、腹泻或便秘、肝肾及心脏毒性等,但多呈轻、中度反应。结论紫杉醇或多西他赛联合表柔比星和环磷酰胺是三阴性乳腺癌的一种安全而有效的新辅助化疗。

作者谢竞霍彦平高峰郝红军

机构地区郑州大学附属郑州中心医院乳腺外科

出处《中国现代药物应用》 2014年第24期93-94,共2页 Chinese Journal of Modern Drug Application

关键词三阴性乳腺癌新辅助化疗紫杉醇/多西他赛表柔比星

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast turnouts. Nature, 2000, 406(6797):747-752.
2Gangi A, Mirocha J, Leong T, et al. Triple-Negative Breast Cancer is Not Associated with Increased Likelihood of Nodal Metastases. Ann Surg Oncol, 2014, 21(13):4098-4"103.
3Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat, 2009, 115(2):423-428.
4Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer, 2008. 113(10):2638-2645.
5Specht J, Gralow JR. Neoadjuvant chemotherapy for locally advanced breast cancer. Semin Radiat Oncol, 2009, 19(4):222-228.
6陈盛,陈灿铭.乳腺癌的新辅助化疗[J].中国癌症杂志,2012,22(9):714-718. 被引量：21
7Abramson VG, Lehmann BD, Ballinger TJ, et al. Suhtyping of triple-negative breast cancer: Implications for therapy. Cancer, 2014(10):100.
8Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 2008, 26(8):1275-1281.
9Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res, 2005, 11(16):5678-5685.

二级参考文献34

1FISHER B, BRYANT J, WOLMARK N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J]. J Clin Oncol, 1998, 16: 2672- 2685.
2SCHWARTZ G F, HORTOBAGYI, G N. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast [ J ] . Cancer, 2004, 100: 2512-2532.
3WOLMARK N, WANG J, MAMOUNAS E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 [ J ] . J Natl Cancer Inst Monogr, 2001: 96-102.
4GUARNERI V, BROGLIO K, KAU S W, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors [ J ]. J Clin Oncol, 2006, 24: 1037-1044.
5MERIC F, MIRZA N Q, BUZDAR A U, et al. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3NoM0 breast cancer [J]. Ann Surg Oncol, 2000, 7: 435-440.
6BRITO R A, VALERO V, BUZDAR A U, et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience [J]. J Clin Oncol, 2001, 19: 628-633.
7MAURIAC L, MACGROGAN G, AVRIL A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow- up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) [J]. Ann Oncol, 1999, 10: 47-52.
8POWLES T J, HICKISH T F, MAKRIS A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer [ J ]. J Clin Oncol, 1995, 13: 547-552.
9SMITH I E, WALSH G, JONES, A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer [J]. J Clin Oncol, 1995, 13: 424-429.
10CHEN A M, MERIC-BERNSTAM F, HUNT K K, et al. Breast conservation after neoadjuvant chemotherapy [J]. Cancer, 2005, 103: 689-695.